Skip to Main Content

INFORMATION FOR

Amer Zeidan, MBBS

Associate Professor of Internal Medicine (Hematology); Director, Early Therapeutics Research, Hematology; Leader, Disease Aligned Research Team (DART) for Leukemias and Myeloid Malignancies, Yale Cancer Center; Chair, Protocol Review Committee (PRC) I, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center

Contact Information

Amer Zeidan, MBBS

Patient Care Location

Mailing Address

  • Hematology

    333 Cedar Street, PO Box 208028

    New Haven, CT 06520-8028

    United States

Appointments

Biography

Amer Zeidan, MBBS, MHS @Dr_AmerZeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division at Yale Cancer Center. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML).

The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches. Dr. Zeidan is also active in health outcomes and comparative effectiveness research for blood cancers and their therapies. Dr. Zeidan has and continues to serve as the principal investigator of many investigator-initiated, cooperative group and industry sponsored clinical trials for myeloid malignancies.

Dr Zeidan also chairs or serves on the steering committees of several large clinical trials of myeloid malignancies. He has served as the vice chair of the Yale Cancer Center Data and Safety Monitoring Committee (YCC DSMC) and currently serves in the independent data and safety monitoring committees of multiple clinical trials. Dr. Zeidan is a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for both MDS and AML and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) in working on early phase clinical trials of novel therapies for myeloid malignancies.

Dr. Zeidan has presented his research in many meetings and has been an invited speaker nationally and internationally. He regularly reviews abstracts for the American Society of Hematology (ASH) annual meetings and chairs meeting sessions. He has been presented on MDS in the ASH Annual highlights meetings in USA and Asia-Pacific as well as the ASH Meeting on Hematologic Malignancies. He is also active within the International Working Group (IWG) of MDS and has previously served on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines panel for MDS.

Dr. Zeidan has received several prestigious awards including the Leukemia and Lymphoma Society Scholar in Clinical Research award, the National Cancer Institute Cancer Clinical Investigator Team Leadership award, the AAMDSIF/Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, the Tito Bastianello Young Investigator Award, the ASCO Young Investigator Award, and multiple other achievement awards. Dr. Zeidan also serves on the editorial board and is a reviewer of several important hematology and oncology journals. He is an author on more than 260 peer-reviewed publications and book chapters.

Education & Training

  • MHS
    Johns Hopkins University (2014)
  • Fellowship
    Johns Hopkins Hospital (2013)
  • Internship
    Rochester General Hospital (2010)
  • MBBS
    University of Jordan (2001)

Honors & Recognition

AwardAwarding OrganizationDate
Scholar in Clinical Research AwardLeukemia and Lymphoma Society2018, 2019, 2020, 2021
Cancer Clinical Investigator Team Leadership AwardNational Cancer Institute2018, 2019, 2020
The Tito Bastianello Young Investigator AwardThe 13th Annual International Symposium on Myelodysplastic Syndromes2015
Cooper Hematology Young Investigator Award2015
Young Investigator Travel GrantThe Society of Oncologic Malignancy2015, 2016
Young Investigator AwardAmerican Society of Clinical Oncology2013, 2014
Travel Award14th Annual Fellows and the 23rd Mayo Clinic Hematology and Oncology Reviews2013
Travel GrantEuropean Group for Blood and Marrow Transplantation2013
Scholarship AwardEuropean Society of Hematology - European Group for Blood and Marrow Transplantation2012
Educational GrantNational Comprehensive Cancer Centers Network2012
Abstract Achievement AwardAmerican Society of Hematology2011, 2012, 2013
First Place in Original Research PresentationRochester General Hospital Annual City-Wide Poster Competition2007
First Place in Clinical Case Poster and PresentationUniversity of Rochester School of Medicine Annual City-Wide Poster Competition2004
Distinguished Academic Performance AwardUniversity of Jordan, College of Medicine1998, 2000, 2001
Certificate of HonorsMinistry of Education1995

Professional Service

OrganizationRoleDate
National Comprehensive Cancer Center NetworkParticipant2015 - 2018
The Swiss Cancer LeagueAd-hoc reviewer2015
The Medical Research Council (MRC) of UKAd-hoc reviewer2015
Edward P. Evans Foundation, MDS Clinical Research Consortium, Aplastic Anemia & MDS International FoundationFellow2012 - 2014

Departments & Organizations